We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) has signed agreements with the Coalition for Epidemic Preparedness Innovations (“CEPI”), Gavi the Vaccine Alliance, and the Serum Institute of India (“SII”) supply its coronavirus vaccine, AZD1222, which it is developing with Oxford University, if successfully developed
The company signed a $750 million agreement with CEPI and Gavi to support the manufacturing, procurement and distribution of 300 million doses of the vaccine. Delivery is expected to start by the end of 2020. The two organizations are backed by Bill and Melinda Gates. The license agreement with SII will enable supply of one billion doses for low and middle-income countries, with a commitment to provide 400 million doses before the end of 2020.
AZD1222 is currently being evaluated in a phase II/III study, with around 10,000 volunteers, which Oxford University initiated recently. Last month, AstraZeneca received more than $1 billion in funding from BARDA to help produce the vaccine. AstraZeneca recently also secured agreements to supply at least 400 million doses to the United States and United Kingdom.
AstraZeneca is also developing its approved drugs including Calquence and Farxiga as a treatment for COVID-19.
AstraZeneca shares have gained 8.1% so far this year against the industry’s decrease of 1.7%.
Meanwhile, the Trump administration has identified AstraZeneca among the five companies, which are most likely to be successful in making vaccines to prevent COVID-19, per a New York Times report.The remaining four companies are Moderna (MRNA - Free Report) , J&J (JNJ - Free Report) , Merck (MRK - Free Report) and Pfizer.
As part of the Operation Warp Speed (OWS) initiative to rapidly develop a vaccine for SARS-CoV-2, the virus that causes COVID-19, the administration narrowed down on the five promising candidates from an extensive list of probable candidates, which are being developed by around a dozen companies. The White House aims to begin widespread vaccination of its citizens by the end of this year.
The identified companies will reportedly receive extra federal funds, help to run their clinical studies and manufacturing assistance.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
AstraZeneca to Ensure Equal Access to Coronavirus Vaccine
AstraZeneca (AZN - Free Report) has signed agreements with the Coalition for Epidemic Preparedness Innovations (“CEPI”), Gavi the Vaccine Alliance, and the Serum Institute of India (“SII”) supply its coronavirus vaccine, AZD1222, which it is developing with Oxford University, if successfully developed
The company signed a $750 million agreement with CEPI and Gavi to support the manufacturing, procurement and distribution of 300 million doses of the vaccine. Delivery is expected to start by the end of 2020. The two organizations are backed by Bill and Melinda Gates. The license agreement with SII will enable supply of one billion doses for low and middle-income countries, with a commitment to provide 400 million doses before the end of 2020.
AZD1222 is currently being evaluated in a phase II/III study, with around 10,000 volunteers, which Oxford University initiated recently. Last month, AstraZeneca received more than $1 billion in funding from BARDA to help produce the vaccine. AstraZeneca recently also secured agreements to supply at least 400 million doses to the United States and United Kingdom.
AstraZeneca is also developing its approved drugs including Calquence and Farxiga as a treatment for COVID-19.
AstraZeneca shares have gained 8.1% so far this year against the industry’s decrease of 1.7%.
Meanwhile, the Trump administration has identified AstraZeneca among the five companies, which are most likely to be successful in making vaccines to prevent COVID-19, per a New York Times report.The remaining four companies are Moderna (MRNA - Free Report) , J&J (JNJ - Free Report) , Merck (MRK - Free Report) and Pfizer.
As part of the Operation Warp Speed (OWS) initiative to rapidly develop a vaccine for SARS-CoV-2, the virus that causes COVID-19, the administration narrowed down on the five promising candidates from an extensive list of probable candidates, which are being developed by around a dozen companies. The White House aims to begin widespread vaccination of its citizens by the end of this year.
The identified companies will reportedly receive extra federal funds, help to run their clinical studies and manufacturing assistance.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank
AstraZeneca currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>